ALLERGEN-SPECIFIC IMMUNOTHERAPY: VACCINES FOR ALLERGIC DISEASES

Allergen-specific immunotherapy (ASIT) is the most effective method of allergy treatment which consists of exposure to small doses of antigen responsible for development of allergic condition in the particular patient. Therefore, one may achieve desensitization to this antigen. The history of ASIT application lasts for more than 100 years, and, over this time, huge clinical evidence for the usage of the method has been accumulated. Use of ASIT causes reduction of allergy symptoms and treatment needs and, moreover, it has the potential for long-term clinical benefit, by preventing the development of allergy and its symptoms. The treatment affects basic immunological mechanisms responsible for the development of clinical symptoms. ASIT is an antiinflammatory, pathogenetic and prophylactic treatment of allergic airway disease. The review considers the results of major clinical trials of the ASIT applications for treatment of allergic diseases of the respiratory system (allergic rhinitis and bronchial asthma). Various schemes of ASIT are discussed including its different variants (injectable and sublingual ASIT), the issues of preparation choice for ASIT from those currently available on the pharmaceutical market, patient selection criteria, and the issues of modern molecular allergodiagnostic (allergic sensitization mapping of the patient at molecular level), in order to optimize them. Immunological mechanisms of ASIT are also considered, since appropriate views are rather contraversial. The ASIT effect is mediated through the following basic immunological mechanisms: the suppressed increase of the eosinophil concentrations, reduced duration of the delayed hypersensitivity phase, as well as initiation and maintenance of the Th2-to-Th1-like immune response transition. Regulatory T-cells play a major role in implementation of the immunological mechanism in ASIT, they have a significant impact on the Th2 response suppression. Such suppression may proceed via increased production of specific IgG antibodies, primarily of IgG4 subtype. The shift of balance between IgE and IgG4 towards IgG4 production is now considered a fundamental condition for successful ASIT. It has been proven that the allergen-specific IgG4 antibodies against IgE persist after discontinuation of the treatment and can provide long-term clinical tolerance. Modern prospectives for development of new forms and species of preparations for ASIT are also reviewed. Two groups of drugs for ASIT have been adopted for clinical practice until now, i.e., allergens and allergoids (allergens chemically modified by treatment with formaldehyde, in order to enhance their immunogenicity and to reduce the incidence of adverse allergic reactions associated with their application). Immunological mechanisms of SLIT (sublingual immunotherapy) are subjected to special consideration. So far, SLIT is the safest and most promising option of ASIT today, its usage is most expedient in pediatric practice.

1. Aalberse R.C., Stapel S.O., Schuurman J., Rispens T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy, 2009, Vol. 39, pp. 469-477.

2. Abramson M., Puy R., Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy, 1999, Vol. 54, no. 10, pp. 1022-1041

3. Abramson M.J., Puy R.M., Weiner J.M. Allergen immunotherapy for asthma. Cochrane Database Syst Rev., 2003, Vol. 4, CD001186.

4. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol., 2011, Vol. 127, no. 1, pp. 18-27

5. Allergen products (Producta allergenica). European Pharmacopeia, 1997, pp. 1063-1068.

6. Alvarez-Cuesta E., Bousquet J. Standards for practical allergen-specific immunotherapy. Allergy, 2006, Vol. 61, Suppl. 82.

7. Alvarez-Cuesta E., Bousquet J., Canonica G.W., Durham S.R., Malling H.J., Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy, 2006, Vol. 61, Suppl. 82, pp. 1-20.

8. Ameal A., Vega-Chicote J.M., Fernandez S., Miranda A., Carmona M.J., Rondon M.C. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy, 2005, Vol. 60, no. 9, pp. 43-83.

9. Andre C., Vatrinet C., Galvain S., Carat F., Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int. Arch. Allergy Immunol., 2000, Vol. 121, no. 3, pp. 229-234.

10. Antico A., Pagani M., Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy, 2006, Vol. 61, no. 10, pp. 1236-1237.

11. Arvidsson M.B., Lowhagen O., Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J. Allergy Clin. Immunol., 2002, Vol. 109, no. 5, pp. 777-783.

12. Bae J.M., Choi Y.Y., Park C.O., Chung K.Y., Lee K.H. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J. Allergy Clin. Immunol., 2013, Vol. 132, no. 1, pp. 110-117

13. Bagnasco M. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j1) administered by noninjectable routes in healthy human beings. J. Allergy Clin. Immunol., 1997, Vol. 100, no. 1, pp. 122-129

14. Baldo B.A. Standardization of allergens. Examination of existing procedures and the likely impact of new techniques on the quality control of extracts. Allergy, 1983, Vol. 38, no. 8, pp. 535-546.

15. Bodtger U., Poulsen L.K., Jacobi H.H., Malling H.J. The safety and efficacy of subcutaneous birch pollen immunotherapy – a one-year, randomised, double-blind, placebo-controlled study. Allergy, 2002, Vol. 57, no. 4, pp. 297-305.

16. Bousquet J., Demoly P. Specific immunotherapy – an optimistic future. Allergy, 2006, Vol. 61, no. 10, pp. 1155-1158.

17. Bousquet J., Demoly P., Michel F.B. Specific immunotherapy in rhinitis and asthma. Ann. Allergy Asthma Immunol., 2001; Vol. 87, no. 1, Suppl. 1, pp. 38-42

18. Bousquet J., Lockey R., Malling H. WHO Position Paper. Allergen Immunotherapy: Therapeutic Vaccines for allergic diseases. Allergy, 1998, Vol. 53, Suppl. 54.

19. Bousquet J., Van Cauwenberge N. Khaltaev and the Workshop Expert Panel. Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy, 2002, Vol. 57, no. 9, pp. 841-845.

20. Bozek A., Gawlik R., Jarzab J. (2014) The Prevention of New Sensitizations by Specific Immunotherapy: A Long-Term Observational Case Control Study. J. Allergy Ther., Vol. 5, p. 182.

21. Buchanan A.D., Green T.D., Jones S.M. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J. Allergy Clin. Immunol., 2008, Vol. 121, no. 1, pp. 270-271.

22. Calamita Z., Saconato H., Pela A.B., Atallah A.N. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy, 2006, Vol. 61, no. 10, pp. 1162-1172.

23. Calamita Z., Saconato H., Pela A.B., Atallah A.N. Efficacy of sublingual immunotherapy in asthma: review of randomized-clinical trials using the Cochrane Collaboration method. Allergy, 2006, Vol. 61, pp. 1162-1172

24. Calderon M., Alves B., Jacobson M., Hurwitz B., Sheikh A., Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev., 2007, Vol. 1, CD001936.

25. Canonica G.W., Baena-Cagnani C.E., Bousquet J., Bousquet P.J., Lockey R.F., Malling H.J. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy, 2007, Vol. 62, no. 3, pp. 317-324

26. Canonica G.W., Passalacqua G. Noninjection routes for immunotherapy. J. Allergy Clin. Immunol., 2003, Vol. 111, no. 3, pp. 437-448; quiz 49.

27. Choi J.S., Ryu H.R., Yoon C.H., Kim J.H., Baek J.O., Roh J.Y., Lee J.R.Treatment of patients with refractory atopic dermatitis sensitized to house dust mites by using sublingual allergen immunotherapy. Ann. Dermatol., 2015, Vol. 27, no. 1, pp. 82-86.

28. Ciepiela O., Zawadzka-Krajewska A., Kotuła I., Demkow U. The influence of sublingual immunotherapy on several parameters of immunological response in children suffering from atopic asthma and allergic rhinitis depending on asthma features. Pneumonol. Alergol. Pol., 2014, Vol. 82, no. 6, pp. 503-510.

29. Colas C., Monzon S., Venturini M., Lezaun A. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J. Allergy Clin. Immunol., 2006, Vol. 117, no. 4, pp. 810-816.

30. Corrigan C.J., Kettner J., Doemer C., Cromwell O., Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy, 2005, Vol. 60, no. 6, pp. 801-807

31. Cox L., Cohn J.R. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann. Allergy Asthma Immunol., 2007, Vol. 98, no. 5, pp. 416-426

32. Cox L., Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann. Allergy Asthma Immunol., 2009, Vol. 103, pp. 451-459.

33. Cox L., Nelson H., Lockey R. Allergen immunotherapy: a practice parameter third update. J. Allergy Clin. Immunol., 2011, Vol. 127, pp. 1-55.

34. Cox L.S., Linnemann D.L., Nolte H., Weldon D., Finegold I., Nelson H.S. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol., 2006, Vol. 117, no. 5, pp. 1021-1035.

35. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med., 2006, Vol. 355, no. 14, pp. 1445-1455.

36. Creticos P.S., Van-Metre T.E., Mardiney M.R., Rosenberg G.L., Norman P.S., Adkinson N.Jr. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J. Allergy Clin. Immunol., 1984, Vol. 73, no. 1, Pt 1, pp. 94-104

37. Criado Molina A., Guerra Pasadas F., Daza Munoz J.C. Immunotherapy with an oral Alternaria extract in childhood asthma. Clinical safety and efficacy and effects on in vivo and in vitro parameters. Allergol. Immunopathol., 2002, Vol. 30, no. 6, pp. 319-330.

38. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol., 2006, Vol. 118, no. 2, pp. 434-440.

39. Des-Roches A., Paradis L., Knani J., Hejjaoui A., Dhivert H., Chanez P. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of efficacy of immunotherapy after its cessation. Allergy, 1996, Vol. 51, pp. 430-433.

40. Des-Roches A., Paradis L., Ménardo J.-L., Bouges S., Daurès J.-P., Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol., 1997, Vol. 99, pp. 450-453.

41. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy, 2003, Vol. 33, no. 2, pp. 206-210

42. Di Rienzo V., Pagani A., Parmiani S., Passalacqua G., Canonica G.W. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy, 1999, Vol. 54, no. 10, pp. 1110-1113.

43. Dreborg S., Frew A. Allergen standardization and skin tests. EAACI Position Paper. Allergy, 1993, Vol. 48, Suppl. 14

44. Dunsky E.H., Goldstein M.F., Dvorin D.J., Belecanech G.A. Anaphylaxis to sublingual immunotherapy. Allergy, 2006, Vol. 61, no. 10, p. 1235.

45. Durham S.R., Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy, 2007, Vol. 62, no. 8, pp. 954-957

46. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O’Brien F., Noble W. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med., 1999, Vol. 341, no. 7, pp. 468-475.

47. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol., 2006, Vol. 117, no. 4, pp. 802-809.

48. Durham S.R., Ying S., Varney V.A., Jacobson M.R., Sudderick R.M., Mackay I.S., Kay A.B., Hamid Q.A. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J. Allergy Clin. Immunol., 1996, Vol. 97, pp. 1356-1365

49. Ebner C., Siemann U., Bohle B., Willheim M., Wiedermann U., Schenk S., Klotz F., Ebner H., Kraft D., Scheiner O. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy, 1997, Vol. 27, pp. 1007-1015.

50. Ferrer M., Burches E., Pelaez A., Munoz A., Hernandez D., Basomba A. Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance. J. Investig. Allergol. Clin. Immunol., 2005, Vol. 15, no. 4, pp. 283-292.

51. Focke M., Marth K., Flicker S., Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin. Exp. Allergy, 2008, Vol. 38, pp. 1400-1408

52. Focke M., Marth K., Valenta R. Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur. J. Clin. Invest. 2009, Vol. 39, pp. 429-436

53. Francis J.N., James L.K., Paraskevopoulos G., Wong C., Calderon M.A., Durham S.R., Till S.J. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol., 2008, Vol. 121, pp. 1120-1125. 54. Frew A.J. Immunotherapy of allergic disease. J. Allergy Clin. Immunol., 2003, Vol. 111, no. 2 Suppl., pp. S712719.

54. Frew A.J. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. Bmj., 1993, Vol. 307, no. 6909, pp. 919-923.

55. Frew A.J., Powell R.J., Corrigan C.J., Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol., 2006, Vol. 117, no. 2, pp. 319-325

56. Global strategy for asthma management and prevention. WHO/NHLBI workshop report: National Institutes of Health, National Heart, Lung and Blood Institute, Publication Number 95-3659; 1995 January 1995

57. Grembiale R.D., Camporota L., Naty S., Tranfa C.M., Djukanovic R., Marsico S.A. Effects of specificimmunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am. J. Respir. Crit. Care Med., 200, Vol. 162, no. 6, pp. 2048-2052.

58. Hamid Q.A., Schotman E., Jacobson M.R., Walker S.M., Durham S.R. Increases in IL-12 messenger RNA + cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J. Allergy Clin. Immunol., 1997, Vol. 99, pp. 254-260.

59. Hirsch S.R., Kalbfleisch J.H., Golbert T.M., Josephson B.M., McConnell L.H., Scanlon R. Rinkel injection therapy: a multicenter controlled study. J. Allergy Clin. Immunol., 1981, Vol. 68, no. 2, pp. 133-155

60. Incorvaia C., Masieri S., Berto P., Scurati S., Frati F. Specific immunotherapy by the sublingual route for respiratory allergy. Allergy Asthma Clin. Immunol., 2010, Vol. 6, no. 1, p. 29

61. International Consensus Report on Diagnosis and Management of Asthma. International Asthma Management Project. Allergy, 1992, Vol. 47, no. 13 Suppl., pp. 1-61.

62. James L.K., Durham S.R. Update on mechanisms of allergen injection immunotherapy. Clin. Exp. Allergy, 2008, Vol. 38, pp. 1074-1088.

63. James L.K., Shamji M.H., Walker S.M., Wilson D.R., Wachholz P.A., Francis J.N., Jacobson M.R., Kimber I., Till S.J., Durham S.R. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J. Allergy Clin. Immunol., 2011, Vol. 127, pp. 509-516.

64. Jutel M., Akdis M., Blaser K., Akdis C.A. Mechanisms of allergen specific immunotherapy – T-cell tolerance and more. Allergy, 2006, Vol. 61, рp. 796-807.

65. Jutel M., Akdis M., Budak F., Aebischer-Casaulta C., Wrzyszcz M., Blaser K., Akdis C.A. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol., 2003, Vol. 33, pp. 1205-1214.

66. Jutel M., Jaeger L., Suck R., Meyer H., Fiebig H., Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol., 2005, Vol. 116, no. 3, pp. 608-613.

67. Kepley C.L., Cambier J.C., Morel P.A., Lujan D., Ortega E., Wilson B.S., Oliver J.M. Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils. J. Allergy Clin. Immunol., 2000, Vol. 106, pp. 337-348.

68. Khinchi M.S., Poulsen L.K., Carat F., Andre C., Hansen A.B., Malling H.J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy, 2004, Vol. 59, no. 1, pp. 45-53.

69. Kleine-Tebbe J., Ribel M., Herold D.A. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy, 2006, Vol. 61, no. 2, p. 181

70. Lockey R.F., Benedict L.M., Turkeltaub P.C., Bukantz S.C. Fatalities from immunotherapy (IT) and skin testing (ST). J. Allergy Clin. Immunol., 1987, Vol. 79, no. 4, pp. 660-677

71. Lombardi C., Giargioni S., Melchiorre A., Tiri A., Falagiani P., Canonica G.W. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy, 2001, Vol. 56, pp. 989-992.

72. Mailling H.J., Weeke B. EAACI immunotherapy position papers. Allergy, 1993, Vol. 48, Suppl. 14, pp. 9-35.

73. Marogna M., Massolo A., Berra D. The type of sensitizing allergen can affect the evolution of respiratory allergy. Allergy, 2006, Vol. 61, pp. 1209-1215

74. Marogna M., Spadolini I., Massolo A., Canonica G.W., Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy, 2004, Vol. 59, no. 11, pp. 1205-1210

75. McCormack P.L., Wagstaff A.J. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs, 2006, Vol. 66, no. 7, pp. 931-938.

76. Meglio P., Bartone E., Plantamura M. A protocol for oral desensitization in children with IgE-mediated cow,s milk allergy. Allergy, 2004, Vol. 59, pp. 980-987.

77. Mirone C., Albert F., Tosi A., Mocchetti F., Mosca S., Giorgino M. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebocontrolled study. Clin. Exp. Allergy, 2004, Vol. 34, no. 9, pp. 1408-1414.

78. Moingeon P., Batard T., Fadel R. et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy, 2006, Vol. 61, no. 2, p.151-165

79. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., Van Overtvelt L. Immune mechanisms of allergenspecific sublingual immunotherapy. Allergy, 2006, Vol. 61, no. 2, pp. 151-165

80. Moller C., Dreborg S., Ferdousi H.A., Halken S., Host A., Jacobsen L. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol., 2002, Vol. 109, no. 2, pp. 251-256.

81. Mosbech H., Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy, 1988, Vol. 43, no. 7, pp. 523-529.

82. Mösges R., Ritter B., Kayoko G., Allekotte S. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust miteand grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets. Acta Dermatovenerol. Alp. Panonica Adriat., 2010, Vol. 19, no. 4, p. 35.

83. Mungan D., Misirligil Z., Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma – a placebo controlled study. Ann. Allergy Asthma Immunol., 1999, Vol. 82, no. 5, pp. 485-490.

84. Nelson H.S. Advances in upper airway diseases and allergen immunotherapy. J. Allergy Clin. Immunol., 2003, Vol. 111, no. 3 Suppl., pp. S793-798.

85. Nelson H.S. Specific immunotherapy with allergen mixes: what is the evidence? Curr. Opin. Allergy Clin. Immunol., 2009, Vol. 9, pp. 549-553.

86. Nelson H.S., Ikle D., Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J. Allergy Clin. Immunol., 1996, Vol. 98, no. 2, pp. 382-388.

87. Nicklas R., Bernstein I., Blessing-Moore J., Fireman S., Gutman A., Lee R. Practice parameters for allergen immunotherapy. J. Allergy Clin. Immunol., 1996, Vol. 6, pp. 1001-1011.

88. Nielsen L., Johnsen C., Mosbech H., Poulsen L., Malling H. Antihistamine premedication in specific cluster immunotherapy: a double-blind, palcebo-controlled study. J. Allergy Clin. Immunol., 1996, Vol. 97, pp. 1207-1213.

89. Niggemann B., Jacobsen L., Dreborg S., Ferdousi H.A., Halken S., Host A. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy, 2006, Vol. 61, no. 7, pp. 855-859.

90. Noon L. Prophylactic inoculation against hay fever. Lancet. 1911, Vol. I, pp. 1572-1573.

91. Nordic Council on Medicines. Registration of allergenic preparations. Nordic Guidelines. 2nd ed. Uppsala: NLN Publications, 1989, no. 23, pp. 1-34.

92. Nouri-Aria K.T., Wachholz P.A., Francis J.N., Jacobson M.R., Walker S.M., Wilcock L.K., Staple S.Q., Aalberse R.C., Till S.J., Durham S.R. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol., 2004, Vol. 172, pp. 3252-3259.

93. Novak N., Bieber T., Allam J.P. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy, 2011, Vol. 66, no. 6, pp. 733-739

94. Novembre E., Galli E., Landi F., Caffarelli C., Pifferi M., De Marco E. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol., 2004, Vol. 114, no. 4, pp. 851-857.

95. Ozdemir C., Kucuksezer U.C., Akdis M., Akdis C.A. Specific immunotherapy and turning off the T cell: how does it work? Ann Allergy Asthma Immunol., 2011, Vol. 107, pp. 381-392.

96. Passalacqua G., Durham S.R. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J. Allergy Clin. Immunol., 2007, Vol. 119, pp. 881-891.

97. Patel P., Salapatek A.M. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev. Vaccines, 2006, Vol. 5, no. 5, pp. 617-629.

98. Patriarca G., Nucera E., Roncallo C. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment. Pharmacol. Ther., 2003, Vol. 17, no. 3, pp. 459-465

99. Penagos M., Compalati E., Tarantini F., Baena-Cagnani R.,Huerta J., Passalacqua G., Canonica G.W. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol., 2006, Vol. 97, no. 2, pp. 141-148.

100. Penagos M., Passalacqua G., Compalati E., Baena-Cagnani C.E., Orozco S., Pedroza A., Canonica G.W. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest., 2008, Vol. 133, no. 3, pp. 599-609.

101. Pham-Thi N., de Blic J., Scheinmann P. Sublingual immunotherapy in the treatment of children. Allergy, 2006, Vol. 61, Suppl. 81, pp. 7-10

102. Pham-Thi N., Scheinmann P., Fadel R., Combebias A., Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol., 2007, Vol. 18, no. 1, pp. 47-57.

103. Polosa R., Li Gotti F., Mangano G., Mastruzzo C., Pistorio M.P., Crimi N. Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy. Clin. Exp. Allergy, 2003, Vol. 33, no. 7, pp. 873-881.

104. Radulovic S., Wilson D., Calderon M., Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy, 2011, Vol. 66, no. 6, pp. 740-752.

105. Rak S., Lowhagen O., Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J. Allergy Clin. Immunol., 1988, Vol. 82, pp. 470-480.

106. Rak S., Yang W.H., Pedersen M.R., Durham S.R. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res., 2007, Vol. 16, no. 2, pp. 191-201.

107. Roberts G., Hurley C., Turcanu V., Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J. Allergy Clin. Immunol., 2006, Vol. 117, no. 2, pp. 263-268.

108. Robinson D.S., Larché M., Durham S. Tregs and allergic disease. J. Clin. Invest., 2004, Vol. 114, pp. 13891397.

109. Roder E., Berger M.Y., Hop W.C., Bernsen R.M., de Groot H., Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J. Allergy Clin. Immunol., 2007, Vol. 119, no. 4, pp. 892-898

110. Ross R.N., Nelson H.S., Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, singleor double-blind, placebo-controlled studies. Clin. Ther. 2000, Vol. 22, no. 3, pp. 342-350.

111. Santos A., Van Ree R. Profilins: mimickers of allergy or relevant allergens? Int. Arch. Allergy Immunol., 2011, Vol. 155, pp. 191-204

112. Savolainen J., Jacobsen L., Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy, 2006, Vol. 61, pp. 1184-1190.

113. Schadlich P.K., Brecht J.G. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics, 2000, Vol. 17, no. 1, pp. 37-52.

114. Shamji M.H., Durham S.R. Mechanisms of immunotherapy to aeroallergens. Clin. Exp. Allergy, 2011, Vol. 41, pp. 1235-1246.

115. Shanahan F. Nutrient Tasting and Signaling Mechanisms in the Gut. Mechanisms of immunologic sensation of intestinal contents. F. Am. J. Physiol., 2000, Vol. 278, pp. 191-196.

116. Staden U., Rolinck-Werninghaus C., Brewe F. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy, 2007, Vol. 62, no. 11, pp. 1261-1269.

117. Suko M., Mori A., Ito K., Okudaira H. Oral immunotherapy may induce T-cell anergy. Int. Arch. Allergy Immunol., 1995, Vol. 107, suppl. 1-3, pp. 278-281

118. Takahashi T., Kuniyasu Y., Toda M. Immunologic self tolerance maintained by CD25+CD4+ naturally anergic and suppressive T-cells: induction of autoimmune disease by breaking their aneigic/suppressivc state. Int. Immunol., 1998, Vol. 10, pp. 1969-1980

119. Taylor A., Verhagen J., Akdis C.A., Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int. Arch. Allergy Immunol., 2004, Vol. 135, no. 1, рp. 73-82

120. TePas E.C., Hoyte E.G., McIntire J.J., Umetsu D.T. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals. Ann. Allergy Asthma Immunol., 2004, Vol. 92, no. 1, pp. 1-2.

121. The current status of allergen immunotherapy (hyposensitisation). Report of a WHO/IUIS working group. Allergy, 1989, Vol. 44, no. 6, pp. 369-379.

122. Turkeltaub P.C., Rastogi S.C., Baer H., Anderson M.C., Norman P.S. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results. J. Allergy Clin. Immunol. 1982, Vol. 70, no. 5, pp. 343-352.

123. Valenta R., Twaroch T., Swoboda I. Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area. Journal of Investigational Allergology and Clinical Immunology, 2007, Vol. 17, Suppl. 1, pp. 36-40.

124. Van-Metre T.E., Adkinson N.Jr., Amodio F.J., Lichtenstein L.M., Mardiney M.R., Norman P.S. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J. Allergy Clin. Immunol., 1980, Vol. 66, no. 6, pp. 500-513.

125. Vidal C., Enrique E., Gonzalo A., Moreno C., Tabar A.I.; Expert Clinical Participants. Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: an Allergists’ Consensus. Clin. Transl. Allergy, 2014, no. 4, p. 36.

126. Wachholz P.A., Nouri-Aria K.T., Wilson D.R., Walker S.M., Verhoef A., Till S.J., Durham S.R. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Immunology, 2002, Vol. 105, pp. 56-62.

127. Wachholz P.A., Soni N.K., Till S.J., Durham S.R. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J. Allergy Clin. Immunol., 2003, Vol. 112, pp. 915-922.

128. Walker S.M., Pajno G.B., Lima M.T., Wilson D.R., Durham S.R. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J. Allergy Clin. Immunol., 2001, Vol. 107, no. 1, pp. 87-93.

129. Walker S.M., Varney V.A., Gaga M., Jacobson M.R., Durham S.R. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy, 1995, Vol. 50, pp. 405-413.

130. Weber R.W. Cross-reactivity of pollen allergens: impact on allergen immunotherapy. Ann. Allergy Asthma Immunol., 2007, Vol. 99, pp. 203-211.

131. Wilson D.R., Lima M.T., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy, 2005, Vol. 60, pp. 412.

132. Wilson D.R., Lima M.T., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy, 2005, Vol. 60, no. 1, pp. 4-12.

133. Wilson D.R., Nouri-Aria K.T., Walker S.M., Pajno G.B., O’Brien F., Jacobson M.R., Mackay I.S., Durham S.R. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J. Allergy Clin. Immunol., 2001, Vol. 107, pp. 971-976.

134. Wilson D.R., Radulovic, Calderon M.A., Durham S.R. Sublingual immunotherapy for allergic rhinitis. Allergy, 2005.

135. Winther L., Malling H.J., Mosbech H. Allergen-specific immunotherapy in birchand grass-pollen-allergic rhinitis. II. Side-effects. Allergy, 2000, Vol. 55, no. 9, pp. 827-835.

136. Winther L., Malling H.J., Moseholm L., Mosbech H. Allergen-specific immunotherapy in birchand grasspollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. Allergy, 2000, Vol. 55, no. 9, pp. 818-826.

137. Wurtzen P.A., Lund G., Lund K., Arvidsson M., Rak S., Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin. Exp. Allergy, 2008, Vol. 38, no. 8, pp. 1290-1301.